BibTex RIS Kaynak Göster
Yıl 2016, Cilt: 26 Sayı: EK-1, 36 - 38, 01.10.2016

Öz

Objective: It is intended to measure the level of knowledge of the population about the radiation frequently agenda from in recent days, to determine the knowledge, attitude, behavior and level of general knowledge about radiation and find out whether the training demands on this issue.Material and Method: We have prepared a questionnaire of 22 questions aimed at determining radiation awareness and knowledge levels in society. The questionnaire contained questions about radiation awareness like age, gender, education level, occupation and cause of radiation, radiation protection methods. Chi-square test was used for statistical analysis. P

Kaynakça

  • Lim LM, Ly N, Anderson D, Yang JC, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010;30:1279-91.
  • Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized co- listin in the treatment of pneumonia due to multidrug-re- sistant Acinetobacter baumannii and Pseudomonas aerugi- nosa. Clin Infect Dis 2005;41:754-7.
  • Korkmaz Ekren P, Töreyin ZN, Berk Takır H, et al. Evalu- ation of nephrotoxicity and prognosis in patients treated with colistin due to hospital-acquired pneumonia. Tuberk Toraks 2017;65:271-81.
  • Pintado V, San Miguel LG, Grill F, et al. Intravenous co- listin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 2008;56:185-90.
  • Falagas ME, Fragoulis KN, KasiakouSK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colis- tin: a prospective evaluation. Int J Antimicrob Agents 2005;26:504-7.
  • Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Sa- fety and efficacy of intravenous colistin (colistin methane sulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2010;35:297- 300.
  • Aydın M, Ergönül Ö, Azap A, et al. Rapid emergence of co- listin resistance and its impact on fatality among healthca- re-associated infections. J Hosp Infect 2018;98:260-3.
  • Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug resistant Pseudo- monas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007;11:402-6.
  • Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimic- rob Agents Chemother 2003;47:2659-62.
  • Balkan II, Dogan M, Durdu B, et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis 2014;46:678-85.
  • Temocin F, Erdinc S, Tulek N, et al. Incidence and risk fac- tors for colistin-associated nephrotoxicity. Jpn J Infect Dis 2015;68:318-20.
  • Phe K, Shields RK, Tverdek FP, et al. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohortstudy. J Antimicrob Chemother 2016;71:3585-7.
  • Omrani AS, Alfahad WA, Shoukri MM, et al. High döşe intravenous colistin methane sulfonate therapy is associa- ted with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia. Ann Clin Microbiol Antimicrob 2015;14:3.
  • Özkarakaş H, Köse I, Zincirlioğlu Ç, et al. Risk factors for colistin-associated nephrotoxicity and mortality in critical- ly ill patients. Turk J Med Sci 2017;47:1165-72.
  • Aydoğan BB, Yıldırım F, Zerman A, et al. Colistin nephro- toxicity in the ICU: Is it different in the geriatric patients? Aging Clin Exp Res 2018;30:573-80.
  • Sriswat N, Hoste EE, Kellum JA. Modern classification of kidney injury. Blood Purif 2010;29:300-7.
  • Strand K, Flaaten H. Severity scoring in the ICU: a review. Acta Anaesthesiol Scand 2008;52:467-78.
  • Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large aca- demic health system. Clin Infect Dis 2011;53:879-84.
  • Akajagbor DS, Wilson SL, Shere-Wolfe KD, et al. Higher incidence of acute kidney injury with intravenous colisti- methate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 2013;57:1300-3.
  • Phe K, Lee Y, Mc Daneld PM, et al. Invitro assessment and multicenter cohort study of comparative nephrotoxicity ra- tes associated with colistimethate versus polymyxin B the- rapy. Antimicrob Agents Chemother 2014;58:2740-6.
  • Hassan MM, Gaifer Z, Al-Zakwani I. Incidence and risk factors of nephrotoxicity in patients on colistimethate sodi- um. Int J Clin Pharm 2018;40:444-9.

Toplumun radyasyon farkındalığı ve radyasyonla ilgili bilgi düzeyi

Yıl 2016, Cilt: 26 Sayı: EK-1, 36 - 38, 01.10.2016

Öz

Giriş: Son dönemlerde sıkça gündeme gelen radyasyon konusunda toplumun bilgi seviyesini ölçmek, radyasyon ile ilgili bilgi, tutum, davranış ve genel kültür seviyesini tespit etmek ve bu konuda eğitim taleplerinin olup olmadığını öğrenmek amaçlanmıştır.Gereç ve Yöntem: Toplumda radyasyon farkındalığı ve bilgi düzeylerini saptamaya yönelik 22 soruluk bir anketi hazırladık. Anket formu; yaş, cinsiyet, eğitim durumu, mesleği ve radyasyon sebepleri, radyasyondan korunma yöntemleri, radyasyon farkındalığı ile ilgili sorular içermekteydi. İstatistiki analizlerde Ki kare testi kullanılmıştır. P

Kaynakça

  • Lim LM, Ly N, Anderson D, Yang JC, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010;30:1279-91.
  • Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized co- listin in the treatment of pneumonia due to multidrug-re- sistant Acinetobacter baumannii and Pseudomonas aerugi- nosa. Clin Infect Dis 2005;41:754-7.
  • Korkmaz Ekren P, Töreyin ZN, Berk Takır H, et al. Evalu- ation of nephrotoxicity and prognosis in patients treated with colistin due to hospital-acquired pneumonia. Tuberk Toraks 2017;65:271-81.
  • Pintado V, San Miguel LG, Grill F, et al. Intravenous co- listin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 2008;56:185-90.
  • Falagas ME, Fragoulis KN, KasiakouSK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colis- tin: a prospective evaluation. Int J Antimicrob Agents 2005;26:504-7.
  • Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Sa- fety and efficacy of intravenous colistin (colistin methane sulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2010;35:297- 300.
  • Aydın M, Ergönül Ö, Azap A, et al. Rapid emergence of co- listin resistance and its impact on fatality among healthca- re-associated infections. J Hosp Infect 2018;98:260-3.
  • Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug resistant Pseudo- monas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007;11:402-6.
  • Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimic- rob Agents Chemother 2003;47:2659-62.
  • Balkan II, Dogan M, Durdu B, et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis 2014;46:678-85.
  • Temocin F, Erdinc S, Tulek N, et al. Incidence and risk fac- tors for colistin-associated nephrotoxicity. Jpn J Infect Dis 2015;68:318-20.
  • Phe K, Shields RK, Tverdek FP, et al. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohortstudy. J Antimicrob Chemother 2016;71:3585-7.
  • Omrani AS, Alfahad WA, Shoukri MM, et al. High döşe intravenous colistin methane sulfonate therapy is associa- ted with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia. Ann Clin Microbiol Antimicrob 2015;14:3.
  • Özkarakaş H, Köse I, Zincirlioğlu Ç, et al. Risk factors for colistin-associated nephrotoxicity and mortality in critical- ly ill patients. Turk J Med Sci 2017;47:1165-72.
  • Aydoğan BB, Yıldırım F, Zerman A, et al. Colistin nephro- toxicity in the ICU: Is it different in the geriatric patients? Aging Clin Exp Res 2018;30:573-80.
  • Sriswat N, Hoste EE, Kellum JA. Modern classification of kidney injury. Blood Purif 2010;29:300-7.
  • Strand K, Flaaten H. Severity scoring in the ICU: a review. Acta Anaesthesiol Scand 2008;52:467-78.
  • Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large aca- demic health system. Clin Infect Dis 2011;53:879-84.
  • Akajagbor DS, Wilson SL, Shere-Wolfe KD, et al. Higher incidence of acute kidney injury with intravenous colisti- methate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 2013;57:1300-3.
  • Phe K, Lee Y, Mc Daneld PM, et al. Invitro assessment and multicenter cohort study of comparative nephrotoxicity ra- tes associated with colistimethate versus polymyxin B the- rapy. Antimicrob Agents Chemother 2014;58:2740-6.
  • Hassan MM, Gaifer Z, Al-Zakwani I. Incidence and risk factors of nephrotoxicity in patients on colistimethate sodi- um. Int J Clin Pharm 2018;40:444-9.
Toplam 21 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Original Article
Yazarlar

Mustafa Koplay Bu kişi benim

Sonjul Maaroof Bu kişi benim

Ahmad Khalil Bu kişi benim

Zeynep Demir Bu kişi benim

Cennet Sidel Bu kişi benim

Ayşegül Öz Bu kişi benim

Burçin Nur Bayındır Bu kişi benim

Medet Armağan Bu kişi benim

Abdülcelil Abiç Bu kişi benim

İsmail Behçet Baz Bu kişi benim

Mesut Sivri Bu kişi benim

İbrahim Varol Bu kişi benim

Yayımlanma Tarihi 1 Ekim 2016
Yayımlandığı Sayı Yıl 2016 Cilt: 26 Sayı: EK-1

Kaynak Göster

Vancouver Koplay M, Maaroof S, Khalil A, Demir Z, Sidel C, Öz A, Bayındır BN, Armağan M, Abiç A, Baz İB, Sivri M, Varol İ. Toplumun radyasyon farkındalığı ve radyasyonla ilgili bilgi düzeyi. Genel Tıp Derg. 2016;26(EK-1):36-8.